SCHEMBL4263283

SCHEMBL4263283

Cc1scc2c(=O)oc(Nc3ccccc3Oc3ccccc3)nc12

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C1R P00736 14/20 0.46
NPC1 O15118 3/20 0.40
ALDH1A1 P00352 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GCK P35557 1/20 0.37
ELANE P08246 2/20 0.36
TSHR P16473 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4263278 0.87 ELANE (0.46) C1RNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL4260494 0.83 C1R (0.46) C1RNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL3453537 0.79 C1R (0.70) C1RNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL4262925 0.79 ELANE (0.49) C1RNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL7033542 0.78 C1R (0.34) C1R
SCHEMBL4259213 0.78 C1R (0.46) C1RNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL3453116 0.77 C1R (0.67) C1RNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL4268147 0.75 C1R (0.47) C1RNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL4264585 0.74 C1R (0.47) C1RNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL4259369 0.74 C1R (0.48) C1RNPC1ALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1446125-B1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LTD (GB) 2009-04-29 EP claimed
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LIMITED (GB) 2009-01-29 US claimed
US-7407954-B2 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity ALIZYME THERAPEUTICS LIMITED (GB) 2008-08-05 US claimed
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity NORGINE B.V. (NL) 2005-04-07 US claimed
EP-1446125-B1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LTD (GB) 2009-04-29 EP disclosed
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LIMITED (GB) 2009-01-29 US disclosed
US-7407954-B2 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity ALIZYME THERAPEUTICS LIMITED (GB) 2008-08-05 US disclosed
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity NORGINE B.V. (NL) 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity LPL, LIPE, LIPC C1R 3110/4885NPC1 725/4885ALDH1A1 281/4885
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY LPL, LIPE, LIPC C1R 3110/4885NPC1 725/4885ALDH1A1 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.